Skip to main content

Table 2 Percentage of patients with at least one infection during the treatment period a

From: A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

 

n/N(%)

 

60 mg (N = 60)

60 mg/120 mg (N = 121)

B cells, cells/μl

  

>50% reduction

10/38 (26%)

29/66 (44%)

≤50% reduction

9/16 (56%)

21/42 (50%)

No reduction

3/5 (60%)

6/10 (60%)

Serum IgG

  

≥5.65 g/L

22/58 (38%)

56/118 (48%)

<5.65 to ≥4.24 g/L

0/1 (0%)

2/2 (100%)

<4.24 g/L

0/0 (0%)

0/1 (0%)

Serum IgM

  

≥0.40 g/L

22/57 (39%)

55/113 (49%)

<0.40 to ≥0.30 g/L

0/2 (0%)

1/4 (25%)

<0.30 g/L

0/0 (0%)

2/4 (50%)

Serum IgA

  

≥ 0.70 g/L

22/59 (37%)

58/120 (48%)

<0.70 to ≥0.525 g/L

0/0 (0%)

0/0 (0%)

<0.525 g/L

0/0 (0%)

0/1 (0%)

  1. aIg, Immunoglobulin; n, Number of patients with at least one infection with analyte measurement in that category; N, Number of patients with analyte measurement in that category; RCT, Randomized control trial. For patients assigned to receive tabalumab in the first or second randomized controlled trial (RCT1 or RCT2, respectively) pretabalumab baseline data were collected at week 0 of RCT1 or RCT2. For patients assigned to receive placebo in RCT1 or RCT2, pretabalumab baseline data were collected either before receiving an optional 80-mg tabalumab rescue dose at week 16 in RCT1 or at the time of open-label extension study entry.